Rubius Therapeutics Inc.

06/23/2021 | Press release | Distributed by Public on 06/23/2021 14:05

Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced[...]